I love medicine - my purpose and joy. I love being with patients. But I do not think it is fair to skim over nor use pejoratives on what physicians complain about - mainly a cumbersome billing, insurance , and administrative system which is what our reps should be solving since

🧵1/ Big news in unresectable stage III NSCLC. The InTRist study is the first randomized trial comparing NAC vs. neoadjuvant chemoimmunotherapy (NAC-ICI) prior to definitive chemoradiotherapy (CRT). Early results are promising. Let’s dig in. 🔍 #LungCancer #RadOnc #ASCO25

Nice, comprehensive overview on #hcc treatments. Would also add the prospective trials comparing SBRT with protons demonstrating non-inferiority v RFA (Kim et al) and better LC v TACE (Bush et al) Dr. Nina Niu Sanford Neil Newman Jeff Ryckman Jordan Kharofa Ted Yanagihara, MD, PhD Laura Dawson

🚨Study activated! NRG GI-011: Ph 3 RCT of Dose-Escalated RT in Locally Advanced Pancreas Cancer (LAP100) Here's a short (7 min) video. Please consider enrolling & reach out w any q's. Thanks to the NIH, NCI, NRG Oncology for supporting our work! clinicaltrials.gov/study/NCT06958… 🙏🙏🙏

Yikes…. Let alone do a lot of the heavy lifting for many cervical cancers

On that note, I wonder if radiation oncology will ever have a community like Radiopaedia one where we can share full stacks of images, volumes, DVHs, and meaningful discussions, all driven by the same communal spirit. It can feel quite lonely in radiation oncology at times.

Executive Summary of the American Radium Society... : American Journal of Clinical Oncology journals.lww.com/amjclinicalonc… Out now! The Amer. Radium Society AUC Guidelines on use of stents in #EsophagealCancer Krishan Jethwa Neil Newman William Small Jr. Percy Lee MD Chris Anker

A modality where you can objectively treat 100 percent of the tumor should not be omitted especially in the modern era Not to mention TACE yields multiple retreatments , and terrible post tace syndrome of sickness and nausea … and financial as well as time toxicity to patients

Some ask if patients with limited metastatic disease can be cured. The answer is clearly yes. We’ve known that since the 1930’s, and it was very clearly articulated in this book from the 1960s. In 2026 we’ll report the final outcomes from SABR-COMET, 10 years after closure.

Please submit and attend ! It’s a great symposium !

Listen to NRG Oncology podcast on global burden of liver cancer and improving radiation for hepatocellular carcinoma w Ted Hong through GI003! Harvard Medical School Mass General Cancer Center Lauren Henke, MD, MSCI National Cancer Institute ASTRO ACRO - American College of Radiation Oncology Amer. Radium Society MassGeneral News NIH

Very nice open access guideline! Pelvic floor PT made the text but not the table. I love it for men and women with lower GI cancers. Dr. Nina Niu Sanford Krishan Jethwa Neil Newman

The semi-annual meetings are always a strong call to action for all who serve NRG Oncology 💪🏼 For those curious about all things membership and how to get involved, our episode with David Scott Miller was both hilarious and illuminating: 🎧 tinyurl.com/23eywwyw 🍎 tinyurl.com/hxsc8sy4

Really excited to see Helio RT as an upcoming trial to help patients with BCLC-C patients (either Extrahepatic disease or a degree of MVI) exploring the addition of SBRT to IO. Furthermore this trial will include child Pugh B7 patients a population that has been excluded from

Time for LAP100(for BED 100) NRG GI -011 👏🏼and a great play on LAP07. Time for the final showdown - can dose escalated RT improve OS in LAPC. Some key highlight: 1.✅ Randomization AFTER neoadjuvant chemo 2. ✅Eligibility for biochemical response and or no radiologic progression

Agreed……. Also if patients have to receive multiple salvage treatments with acute (post TACE syndrome) and longterm AEs (worsening hepatic parenchymal damage) then are we seeking patient centric liver directed therapies ?

🟠1L treatments of advanced pancreatic cancer ➡️mFOLFIRINOX or S-IROX vs Gem-nab-paclitaxel GENERATE, JCOG1611 Journal of Clinical Oncology ❌mFOLFIRINOX is not superior to Gem-nabPacli ❌No difference in OS, PFS and ORR 👉ascopubs.org/doi/pdf/10.120… ASCO OncoAlert #cancer #oncology #pancreatic

Does the addition of MDT to standard of care continuous ADT improve outcomes for oligomet prostate ca? Happy to share the results of EXTEND evaluating this question alongside PI Chad Tang, MD & many others